ALSO NOTED: BMS gets priority review for dastatinib; FDA votes to recommend Cubicin; and much more...
Free newsletter via e-mail
Tools
> Bristol-Myers Squibb has gained priority review status for its oncology therapy dastatinib. Report
> An FDA committee has voted to recommend Cubicin. Release
> Biovail has restructured and announced that its chief scientific officer is stepping down. Report
> Advanced Magnetics plans to raise $31.7 million in a stock offering. Release
And Finally... Researches think genetics may be the underlying cause of anorexia. Article
SHARE
WITH: